KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to “Strong-Buy” at Citizens Jmp

KalVista Pharmaceuticals (NASDAQ:KALV) was upgraded by stock analysts at Citizens Jmp to a “strong-buy” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

Several other research analysts have also weighed in on KALV. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, JMP Securities started coverage on KalVista Pharmaceuticals in a report on Friday. They set an “outperform” rating and a $19.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $23.80.

KalVista Pharmaceuticals Price Performance

NASDAQ KALV opened at $8.91 on Friday. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $16.88. The stock’s 50 day simple moving average is $8.83 and its 200 day simple moving average is $10.90. The firm has a market cap of $440.33 million, a PE ratio of -2.45 and a beta of 0.86.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. As a group, equities analysts expect that KalVista Pharmaceuticals will post -3.56 earnings per share for the current year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,627 shares of KalVista Pharmaceuticals stock in a transaction on Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the transaction, the chief executive officer now directly owns 274,596 shares of the company’s stock, valued at $2,677,311. The trade was a 2.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock valued at $304,086 over the last 90 days. Company insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently made changes to their positions in KALV. The Manufacturers Life Insurance Company grew its holdings in KalVista Pharmaceuticals by 27.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 3,314 shares in the last quarter. SG Americas Securities LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $153,000. China Universal Asset Management Co. Ltd. grew its position in shares of KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,328 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its stake in KalVista Pharmaceuticals by 23.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after acquiring an additional 121,615 shares during the last quarter. Finally, Emerald Advisers LLC lifted its position in KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after purchasing an additional 192,091 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).